Background/Aims: Breast cancer is the most common cancer in women worldwide, and within this cancer type, triple-negative breast cancers have the worst prognosis. The identification of new genes associated with triple-negative breast cancer progression is crucial for developing more specific anti-cancer targeted therapies, which could lead to a better management of these patients. In this context, we have recently demonstrated that SMARCAD1, a DEAD/H box-containing helicase, is involved in breast cancer cell migration, invasion, and metastasis. The aim of this study was to investigate the impact of the stable knockdown of SMARCAD1 on human breast cancer cell progression. Methods: Using two different designs of shRNA targeting SMARCAD1, we investigated the impact of the stable knockdown of SMARCAD1 on human breast cancer cell proliferation and colony growth in vitro and on tumour growth in chick embryo and nude mouse xenograft models in vivo using MDA-MB-231 (ER We found that SMARCAD1 knockdown resulted in a significant decrease in breast cancer cell proliferation and colony formation, leading to the significant inhibition of tumour growth in both the chick embryo and nude mouse xenograft models. This inhibition was due, at least in part, to a decrease in IKKβ expression. Conclusion: These results indicate that SMARCAD1 is involved in breast cancer progression and can be a promising target for breast cancer therapy.
SMARCAD1 in Breast Cancer Progression
We found that SMARCAD1 knockdown resulted in a significant decrease in breast cancer cell proliferation and colony formation, leading to the significant inhibition of tumour growth in both the chick embryo and nude mouse xenograft models. This inhibition was due, at least in part, to a decrease in IKKβ expression. Conclusion: These results indicate that SMARCAD1 is involved in breast cancer progression and can be a promising target for breast cancer therapy.
Introduction
Breast cancer is the most common malignancy among women worldwide and the leading cause of cancer death despite the remarkable progress made in its treatment in recent years. Identification of new oncogenic partners will further improve our understanding of this disease and will contribute to the development of novel targeted therapies that will enhance the survival of breast cancer patients. In this context, it has been reported that cyclineG1 is highly expressed in triple-negative breast cancer (TNBC) cell lines and tissues treated with paclitaxel, inducing polyploidy and resistance, indicating that cyclineG1 is a poor prognostic biomarker in TNBC patients treated with paclitaxel [1] .
SMARCAD1 (SWI/SNF-related, Matrix-associated, Actin-dependent Regulator of Chromatin, containing DEAD/H box 1) is a member of the DEAD/H box-containing helicases which include proteins essential for replication, repair, and transcription. In the last few years, studies have pointed to a role for human SMARCAD1 and its yeast ortholog, Fun30, in remodelling chromatin structure [2, 3] . Although most of the data support a role for these chromatin remodelers in gene silencing by forming heterochromatin around centromeres, telomeres, or mating type loci (in yeast), there is also evidence highlighting a possible role for SMARCAD1 in establishing euchromatin formation, suggesting a dual effect on chromatin condensation [3] [4] [5] [6] [7] [8] [9] . Moreover, SMARCAD1 and Fun30 have both been shown to play important roles in long-range DNA end resection [10] [11] [12] [13] , which is one of the initial steps during DNA double-stranded breaks (DSBs) repair mediated through homologous recombination pathway. Consistent with the recruitment of Fun30 to DSBs, SMARCAD1 was also found to be recruited to laser-induced DNA damage sites and nuclease-induced DSBs, where γH2AX is co-localised [12] . More recently, the functions of Fun30 as a target of CDK phosphorylation [10, 11, 14] and SMARCAD1 at DSBs are found to be cell cycle regulated [15, 16] . All these data suggest an evolutionarily conserved role for the Fun30 and SMARCAD1 chromatin remodelers.
The Fun30 gene is not essential for the survival of yeast, but its loss can lead to genomic instability [5, 8] . Interestingly, overexpression of Fun30 was also shown to lead to genomic instability [17] . In addition, SMARCAD1 overexpression has been observed in a retroviral E1A-expressing HeLa cell line with an increased capacity for gene reactivation by genomic rearrangements, suggesting a role for SMARCAD1 in genomic instability [18] . In higher eukaryotes, genomic instability can lead to cell death or cancer development. Interestingly, SMARCAD1 has been mapped to chromosome 4q22-23, a region rich in break points and deletion mutants of genes involved in several human diseases, notably soft tissue leiomyosarcoma, hepatocellular carcinoma, and hematologic malignancies [18] . Similarly, it was reported that a loss of heterozygosity in the tissues of patients with head and neck cancers occurred frequently in chromosome region 4q22-35, where SMARCAD1 is located. These data suggest a possible tumour suppressor role for SMARCAD1 [19] . Moreover, when the gene expression profile was used to predict survival time for patients with bladder cancer, it was found that the expression of SMARCAD1 was a predictor of an increased survival time [20] . In another study, SNPs were identified as predictors for sensitivity to capecitabine, a drug that is widely used in the treatment of breast, colorectal, and gastric cancers [21] . Genomewide association studies on lymphoblastoid cell lines from individuals around the world have identified many SNPs in SMARCAD1, in addition to a missense variant, rs11722476, in which a serine was changed to asparagine, suggesting that SMARCAD1 polymorphisms may have a role in capecitabine sensitivity [21] .
Working towards the goal of understanding the role of SMARCAD1 in cancer, we have recently shown that MDA-MB-231 cells, which are highly invasive and metastatic cancer cells, had a higher level of SMARCAD1 expression compared to non-invasive cells [22] . In this study, we demonstrated that SMARCAD1 knockdown in this cell line caused an increase in cell-cell adhesion and a significant decrease in cell migration, invasion, and metastasis, mediated at least in part by the strong inhibition of signal transducer and activator of transcription 3 (STAT3) phosphorylation [22] .
The involvement of SMARCAD1 in cancer cell proliferation, colony and tumour growth has never been explored. The aim of this study was to investigate the impact of the stable knockdown of SMARCAD1 on human breast cancer cell proliferation and colony growth in vitro and on tumour growth in vivo using the oestrogen receptor (ER)-negative MDA-MB-231 and (ER)-positive T47D human breast cancer cell lines.
Materials and Methods

Immunohistochemistry of SMARCAD1 in normal and neoplastic human mammary gland tissues
Mammary gland tissue array slides were purchased from US Biomax (Rockville, MD, U.S.A.). US Biomax states that all human tissue collections were obtained at certified hospitals under the highest ethical standards. Each tissue array slide included multiple sections from invasive ductal, lobular, and apocrine breast carcinomas. In addition, the array included non-cancerous normal mammary gland tissues. Tissue sections were deparaffinised, rehydrated, and washed in phosphate-buffered saline (PBS). To inhibit endogenous peroxidase activity, the sections were incubated in 3% hydrogen peroxide in methanol for 1 h. To block non-specific binding, the sections were incubated in 1% bovine serum albumin (BSA) containing 0.5% Tween-20 in PBS for 45 min. The sections were then incubated overnight at 4˚C with well-characterised goat polyclonal anti-SMARCAD1 antibody from Santa Cruz Biotechnology, Inc. (Dallas, Texas, U.S.A.; final dilution, 1:50). Following a PBS wash, the tissue sections were incubated with biotinylated donkey anti-goat immunoglobulin G obtained from Jackson ImmunoResearch (West Grove, PA, U.S.A.) at a 1:100 dilution for 1 h. Tissue sections were washed in PBS and then incubated in extravidin/peroxidase conjugate (SigmaAldrich, St. Louis, MO, U.S.A.) at a 1:500 dilution for 1 h. The antigen-antibody binding sites were revealed using 3, 3'-diaminobenzidine tetrahydrochloride from Sigma.
Cell culture
The MDA-MB-231 (ER -/PR -/HER2 -) and T47D (ER + /PR +/-/HER2 -) human breast cancer cell lines were maintained in DMEM supplemented with antibiotics (penicillin 50 U/ml; streptomycin 50 µg/ml) and 10% foetal bovine serum (Hyclone, Cramlington, UK) at 37°C. The culture medium was changed every 3 days, and cells were passaged once a week when the culture reached 95% confluence. In all experiments, cell viability was higher than 99% using trypan blue dye exclusion.
Western blot analysis of IKK protein expression in breast cancer cells
Total cellular proteins from the human breast cancer cells transduced with SMARCAD1-shRNAs (SMARCAD1-shRNA1 and SMARCAD1-shRNA2), IKKβ-shRNAs (IKKβ-shRNA1, IKKβ-shRNA2, and IKKβ-shRNA3), or control sequences (Control-shRNA) were isolated as described previously [23] using RIPA buffer (25mM Tris.HCl pH 7.6, 1% nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 0.5% protease inhibitors cocktail, 1% PMSF, 1% phosphatase inhibitor cocktail). The whole cell lysates were recovered by centrifugation at 14, 000 rpm for 20 minutes at 4°C to remove insoluble material, and protein concentration of lysates were determined by BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Proteins (30-50 µg) were separated by SDS-PAGE gel to evaluate the expression of IKKα, IKKβ, and IKKγ. After electrophoresis, the proteins were transferred onto a nitrocellulose membrane, blocked for 1 h at room temperature with 5% non-fat milk in TBST (TBS and 0.05% Tween 20) , and then probed with specific primary antibodies of IKKα, IKKβ, and IKKγ (Cell Signaling, Beverly, MA, USA, 1:500) and β-actin (Santa Cruz, California, USA, 1:1000) overnight at 4 °C. The blots were washed and exposed to secondary antibodies. Immunoreactive bands were detected using ECL chemiluminescent substrate (Thermo Fisher Scientific, Waltham, Massachusetts, US) and chemiluminescence was detected using the LiCOR C-DiGit blot scanner (LI-COR Biotechnology, US). Membrane stripping was performed by incubating the membrane in Restore Western blot stripping buffer (Thermo Fisher Scientific, Waltham, Massachusetts, US) according to the manufacturer's instructions. Densitometry analysis was performed using an HP Deskjet F4180 Scanner with ImageJ software. The intensities of the IKKβ bands were normalised to the intensities of the corresponding β-actin bands. 
Knockdown of IKKβ in MDA-MB-231 cells
Cells were seeded at a density of 20, 000 cells/well in 96-well plates and allowed to attach for 24 h. Cells were transduced with either SMARTvector 2.0 Lentiviral shRNA particles targeting IKKβ or SMARTvector 2.0 Non-Targeting control particles (Dharmacon Thermo Scientific, US) that contained a puromycin resistance gene for clone selection and GFP for identification of positive clones. Three different designs of Lentiviral shRNA particles targeting IKKβ were used. After 72 h of transfection, cells stably expressing IKKβ-shRNA and the Control-shRNA were selected following the manufacturer's instructions (Dharmacon Thermo Scientific, US). Briefly, growth medium was aspirated from the cells and replaced with fresh selection medium containing 10 µg/mL puromycin, which was replaced every 3 days with freshly prepared selection medium for approximately 4 weeks. Multiple clones were expanded, harvested, and prepared for western blot analyses of IKKβ expression.
Cell quantification and colony formation assays MDA-MB-231 cells transduced with SMARCAD1-shRNAs (SMARCAD1-shRNA1 and SMARCAD1-shRNA2), IKKβ-shRNAs (IKKβ-shRNA1, IKKβ-shRNA2, and IKKβ-shRNA3), or control sequences (ControlshRNA) were plated at a density of 50, 000 cells/well in 6-well tissue culture dishes supplemented with 10% FBS. Cells were trypsinized, collected in 1 ml of medium, and counted at an appropriate dilution every day for 4 consecutive days. The same protocol was applied to the T47D cells transduced with SMARCAD1-shRNAs (SMARCAD1-shRNA1 and SMARCAD1-shRNA2) or control sequences (Control-shRNA).
For the colony formation assay, a layer of agar containing 1 ml of 2.4% low-melting-temperature agar dissolved in distilled water was poured into the wells of a 6-well cell culture dish and allowed to set at 4°C for 5 min; the dish was then incubated at 37°C for 30 min. A second layer (2.9 ml) containing 0.3% of lowmelting-temperature agar dissolved in growth medium containing cells stably transduced with SMARCAD1-shRNAs, IKKβ-shRNAs, or control-shRNA (20×10 3 cells/ml) was placed on top of the first layer and allowed to set at 4°C for 5 min. After an incubation of 30 min to 1 h in a humidified incubator at 37°C, growth medium (2 ml) was added on top of the second layer, and the cells were incubated in a humidified incubator at 37°C for 3 weeks. The medium was changed twice a week. At the end of the experiment, colonies were stained for 1 h with 2% Giemsa stain and incubated with PBS overnight to remove excess Giemsa stain. The colonies were photographed and scored.
Impact of SMARCAD1 silencing on tumour growth in chick embryos and nude mice in vivo
Chick embryo tumour growth assay. Fertilised White Leghorn eggs were incubated at 38°C and 60% humidity for 10 d. At this time (E10), the chorioallantoic membrane (CAM) was dropped by drilling a small hole through the eggshell into the air sac, and a 1 cm 2 window was cut in the eggshell above the CAM. MDA-MB-231 cells stably transduced with SMARCAD1-shRNAs (SMARCAD1-shRNA1, SMARCAD1-shRNA2) or control sequences (Control-shRNA) were trypsinized, washed with complete medium, and suspended in serum-free DMEM. A 50 µl inoculum of 1 X 10 6 cells was added onto the CAM of each egg, for a total of 15 eggs per cell line (to ensure a sufficient number of surviving embryos at the end of the experiments). One day later, tumours had begun to be detectable. At E19, the upper portion of the CAM was removed and transferred to PBS, and the tumours were then carefully cut away from normal CAM tissues and weighed. According to French legislation, no ethical approval was needed for scientific experiments using oviparous embryos (decree n° 2013-118, February 1, 2013; art. R-214-88). Animal studies were performed under animal experimentation permit N° 381029 to Jean Viallet and animal experimentation permit N° B3851610001 to Institut Albert Bonniot.
Tumour growth assay in nude mice in vivo. Six-week-old athymic NMRI nude mice (nu/nu, Charles River, Suizfeld, Germany) were maintained under specified pathogen-free conditions. MDA-MB-231 human breast cancer cells stably transduced with SMARCAD1-shRNA1 or control sequences (Control-shRNA) (5 x 10 6 cells mixed v/v with Matrigel) were injected subcutaneously into the lateral flanks of the mice. Throughout this study, nude mice were housed in filtered-air laminar flow cabinets and manipulated under aseptic conditions. The animal experiments were performed according to the protocol approved by the animal ethics committee at the college of Medicine and Health Sciences/UAE University. Tumour dimensions were measured with callipers every week. Tumour volumes (V) were calculated using the following formula: V = a x b 2 x 0.4, with "a" being the length and "b" the width of the tumour. The animals were sacrificed 10 weeks
Results
Expression of SMARCAD1 in mammary gland tissues
In the normal human mammary gland, there were scattered cells positively stained for SMARCAD1; these were located mostly in the small alveolar/ductal profiles (Fig. 1) . In the ductal carcinoma tissue, SMARCAD1-labelled cells were found in cellular groups of the glandular structures (Fig. 1 ). In the highly invasive lobular carcinoma tissue, almost all individually invasive cancer cells strongly expressed SMARCAD1 protein (Fig. 1) . In contrast, the apocrine cancer tissue showed very weak or no binding of the antibody with the tumour cells (Fig. 1) .
SMARCAD1 silencing decreased MDA-MB-231 and T47D cell proliferation and colony growth
The MDA-MB-231 and T47D SMARCAD1-silenced cells exhibited a significant decrease in their proliferation rate compared with the shRNA control cells ( Fig. 2A and Fig. 2B ). Similar to the decrease in cell proliferation, SMARCAD1 silencing strongly inhibited the abilities of the MDA-MB-231 cells (Fig. 2C and Fig. 2E ) and T47D cells (Fig. 2D and Fig. 2F ) to form colonies in soft agar.
The decreases in cell proliferation and colony growth exhibited by the SMARCAD1-silenced cells strongly suggested that the growth of these cells in vivo would be affected. To demonstrate this effect, we focused our investigation in vivo on the highly tumorigenic triplenegative (ER-/PR-/HER2-) MDA-MB-231 cell line. The triple-negative breast cancer represents a relatively small proportion of all breast cancers (10-15%). However, it has a poor prognosis and constitutes a large proportion of breast cancer-related death [24] .
First, we assessed the effects of SMARCAD1 silencing on the tumour growth potential of the MDA-MB-231 cells in vivo in a chick embryo model. MDA-MB-231 cells transduced with SMARCAD1-shRNAs (SMARCAD1-shRNA1 and SMARCAD1-shRNA2) or control sequences (ControlshRNA) were grafted on the chorioallantoic membrane; the tumours that formed were recovered from the upper CAM and weighed at E19. We found that SMARCAD1 silencing significantly inhibited the tumour growth of the MDA-MB-231-SMARCAD1-shRNA1 and MDA-MB-231-SMARCAD1-shRNA2 xenografts by 62% and 65%, respectively (Fig. 3A) . 
T-47D
Based on the similar tumour growth inhibition results obtained in the chick embryo assay using the two SMARCAD1-silenced cell types, we decided to use only one cell line, MDA-MB-231-SMARCAD1-shRNA1, in an in vivo nude mouse model to confirm the effect of SMARCAD1 silencing on tumour growth. As in the chick embryo assay, silencing SMARCAD1 strongly inhibited MDA-MB-231 tumour growth (178 mm 3 +/-102.5, *P < 0.05) compared with control-shRNA (595.3 mm 3 +/-86) (Fig. 3B) . A similar difference in tumour weight was found at the end of the experiment (0.57 +/-0.29 g versus 1.37 +/-0.16 g, *P < 0.05) (Fig. 3C) .
SMARCAD1 knockdown reduced the expression of IKK-β kinase
The transcription factor NF-κB is constitutively activated in many cancers, including breast cancer, leading to the transcription of a vast array of genes linked to cancer cells proliferation [25] . The IKK kinases are the core element of the NF-κB cascade and their activities have been shown to be elevated in both breast carcinoma cell lines and primary tumours [26] . In this context, we demonstrated that the inhibition of cell proliferation, colony formation, and tumour growth resulting from the silencing of SMARCAD1 was correlated with a significant decrease in the expression IKK-β in both SMARCAD1-silenced cells MDA-MB-231 and T47D. However, the expression of IKK-α and IKKγ were not affected by the knock-down of SMARCAD1 (Fig. 4A-D) .
Impact of IKK-β knockdown on MDA-MB-231 cell proliferation and colony growth
Based on the abovementioned results, we decided to silence IKK-β in MDA-MB-231 cells and investigate the impact of its knock-down on cell proliferation and colony growth. MDA-MB-231 cells were stably transduced with three different designs of SMARTvector 2.0 Lentiviral shRNA particles targeting IKK-β. Control cells were transduced with SMARTvector 2.0 Non-Targeting control particles. Positive clones were selected under puromycin and analysed using western blotting to confirm the specific IKK-β silencing. These three IKK-β-targeting shRNAs (IKK-β-shRNA1, IKK-β-shRNA2, and IKK-β-shRNA3) induced respectively 87%, 68%, and 96% decreases in the IKK-β protein level in the MDA-MB-231 cells (Fig. 5A ). In addition, in cells transduced with the three IKK-β-targeting shRNAs (IKK-β-shRNA1, IKK-β-shRNA2, and IKK-β-shRNA3), there was no impact on IKK-α protein, confirming the selectivity of this silencing (Fig. 5A) . The three MDA-MB-231 IKK-β-silenced cells exhibited a significant decrease (P<0.01) in their proliferation rates compared with the shRNA control cells (Fig. 5B) . Similar to the decrease in cell proliferation, IKK-β silencing decreased the growth of the three MDA-MB-231 IKK-β-silenced colonies in soft agar (Fig. 5C ). However, this inhibition did not reach the statistical significance, but was similar to the mild decreases in MDA-MB-231 growth after transient transfection with IKK-β siRNA [27] . Therefore, these results demonstrated that the inhibition of breast cancer cell proliferation, colony formation, and tumour growth resulting from SMARCAD1 knock-down were associated at least in part with a strong decrease in IKK-β expression. 
Discussion
We have found that SMARCAD1 knockdown resulted in a significant decrease in breast cancer cell proliferation and colony formation, leading to the inhibition of tumour growth in chick embryo and nude mouse xenograft models. This inhibition was due at least in part to a decrease in the expression of IKKβ, a key kinase of the NF-κB cascade.
The NF-κB pathway is involved in normal growth and development and in all hallmarks of cancer progression including cell proliferation. The transcription factor NF-κB is composed of five members: RelA (p65), RelB, c-Rel, NF-kB1 (p50 and its precursor p105), and NF-kB2 (p52 and its precursor p100). The activity of NF-κB is regulated by the inhibitor of kB (IκB-α) protein. In resting cells, IκB-α inhibits the p65 and p50 NF-κB complex by trapping it in the cytoplasm [28] . We have previously reported that the over-expression IκB-α inhibited NF-κB activity induced by the src oncogene and reduced cancer cell proliferation and tumour growth [29] .
Multiple extra-and intracellular signals, including cellular stress, pro-inflammatory stimuli, and oncogene signals, activate the NF-κB signalling pathway. In response to cellular stimulation, IκB-α is phosphorylated by the NEMO-IKK-α/β complex, ubiquitinated, and degraded by the proteasome, allowing the release and nuclear translocation of the p50/p65 NF-κB complex, where it regulates the expression of target genes involved in immune responses, inflammation, and cancer. Therefore, this classical canonical NF-κB pathway activation requires IKK-β kinase; however, the second non-canonical NF-κB pathway, which is based on the phosphorylation-induced processing of inactive p100 protein to its active p52 derivative instead of the degradation of IκB-α, requires IKK-α kinase [30] . IKK-β and IKKγ are essential components of the canonical NF-κB pathway, whereas IKK-α, but not IKK-β or IKKγ, is required for the non-canonical NF-κB signalling [31] . Activation of IKK-α has been implicated in the development and proliferation of the breast mammary glands [32] and IKK activities have been shown to be elevated in both breast carcinoma cell lines and primary tumours [26] . Pharmacological inhibitors of NF-κB pathway and mainly inhibitors of the IKK-β kinase developed over the past 15 years have been shown to have a good efficacy as single agents and in combination with chemotherapeutic drugs as reported in several preclinical studies, but unfortunately, none of these pharmacological inhibitors have been approved for the clinical use [33] . We recently reported that the inhibition of breast cancer cell migration and invasion in the SMARCAD1 knock-down cells was mainly due to a strong inhibition of STAT3 phosphorylation [22] . STAT3 is constitutively activated in more than 40% of breast cancers, and its role in cancer cell proliferation, colony formation, and tumour growth is now well established [34, 35] .
Conclusion
Based on the current results and our previously published data, we can conclude that SMARCAD1 knock-down decreased breast cancer cell proliferation, colony formation, and tumour growth via a down-regulation of IKK-β expression and a decrease of STAT3 phosphorylation.
